ERIN ZIMMERMAN: Open Payments
NPI 1871091058 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,300 in 82 payments from 18 companies in 2025. Trend: 2023 $1,331 · 2024 $993 · 2025 $1,300
Food & beverage: $1,300
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 26 | $343 |
| ABBVIE INC. | 8 | $156 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $137 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $114 |
| Boston Scientific Corporation | 1 | $67 |
| GENZYME CORPORATION | 3 | $60 |
| Regeneron Healthcare Solutions, Inc. | 2 | $52 |
| Ipsen Biopharmaceuticals, Inc | 2 | $49 |
| Phathom Pharmaceuticals, Inc. | 8 | $49 |
| Gilead Sciences, Inc. | 2 | $45 |
Products named: TREMFYA, ENTYVIO, XIFAXAN, DUPIXENT, OverStitch Endoscopic Suturing System, RINVOQ, IQIRVO, VOQUEZNA.
Industry payments across NE — which companies pay providers there.
